Memorial Sloan Kettering Cancer Center

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

A new exploratory analysis of the HIMALAYA phase III trial shows that 19.6% of patients with unresectable hepatocellular carcinoma treated with STRIDE immunotherapy remained alive after five years, compared to 9.4% with sorafenib.

Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.

QBiotics reported an 80% objective response rate in Stage 1 of its Phase IIa trial evaluating tigilanol tiglate in 10 patients with advanced soft tissue sarcoma.

NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.

Lisocabtagene maraleucel (liso-cel) demonstrated a 95.5% overall response rate and 62.1% complete response rate in 66 patients with relapsed/refractory marginal zone lymphoma in the TRANSCEND FL trial.

Curadev Pharma and Memorial Sloan Kettering Cancer Center are expanding their collaboration through MSK's Therapeutics Accelerator program to advance development of CRD3874-SI, a first-in-class allosteric STING agonist.

ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable.

Minerva Biotechnologies published research demonstrating that MUC1*-targeted CAR-T cells with 1XX mutations show increased persistence and ability to kill low antigen-expressing cancer cells in animal models.

Juri Biosciences, a TCG Labs Soleil portfolio company, has entered into a worldwide licensing agreement with EpimAb Biotherapeutics for exclusive global rights to a KLK2-targeted T-cell engager for metastatic prostate cancer treatment.